Aldose reductase inhibitor, epalrestat, reduces lipid hydroperoxides in type 2 diabetes.
Ohmura C, Watada H, Azuma K, Shimizu T, Kanazawa A, Ikeda F, Yoshihara T, Fujitani Y, Hirose T, Tanaka Y, Kawamori R.
Ohmura C, et al. Among authors: ikeda f.
Endocr J. 2009;56(1):149-56. doi: 10.1507/endocrj.k08e-237. Epub 2008 Nov 8.
Endocr J. 2009.
PMID: 18997444
Free article.
Clinical Trial.